Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of US $17.7 billion (12.7 billion euro) while spending 21 percent of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

References:

  1. Miller et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Abstract LBA1, European Society of Medical Oncology (ESMO) Congress, Milan, October 2010.
  2. Miller et al. Phase IIb/III trial of afatinib (BIBW 2992) + best supportive care (BSC) vs. placebo + BSC in patients failing 1–2 lines of chemotherapy and erlotinib/gefitinib (LUX-Lung 1).  Oral presentation, European Society of Medical Oncology (ESMO) Congress, Milan, October 2010.
  3. Yang et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lu
    '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  Intec Pharma Ltd. (the "Company") (NASDAQ: ... developing drugs based on its proprietary Accordion Pill platform ... offering in the United States ... to the public of $6.00 per ordinary share, before ... are being offered by the Company.  In addition, the ...
(Date:8/4/2015)... , August 4, 2015 ... with market overview, trends, DRO analysis, market segmentation, ... competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC ...
(Date:8/4/2015)... -- Second Quarter 2015 Highlights: , ... of 2014 , Net earnings attributable to Team Health ... adjustments , Diluted net earnings per share of $0.39; ... to $99.4 million 2015 Outlook: , ... 24.0% to 26.0%; Adjusted EBITDA margin remains between 10.5% and ...
Breaking Medicine Technology:Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30
... 2011 The grand opening ceremony for the world,s largest ... RNL BIO ( www.rnl.co.kr ), South Korea,s premier ... stem cell medical center in Beijing, China. Beijing RNL Stem ... Research Institute" (President : Li Hailing, www.yandaco.com ). Beijing ...
... harder to crush version of OxyContin® has a lower ... at a conference of law enforcement officers today. Last ... announced that every day 100 people die from drug ... pain relievers. A new formulation of the opioid pain ...
Cached Medicine Technology:RNL Opens the World's Largest Stem Cell Medical Center in Beijing, China 2New OxyContin® Has Lower Street Price Than Old Crushable Formulation 2
(Date:8/4/2015)... ... 04, 2015 , ... Driving skills may decline with age, ... the August 2015 Harvard Health Letter. , "Age and health conditions aren't enough ... assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated Beth Israel ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... party supplies, arts and crafts, toys, novelties, and school supplies, has developed engaging ... , The exclusive collection includes student rewards, classroom decorations, crafts and ...
(Date:8/4/2015)... ... ... than 700 years of marital bliss were celebrated as 13 couples from Friendship Village ... and Richard Oas lead the non-denominational service for married couples wishing to reaffirm their ... the Moonlight Serenade Orchestra and a special honeymoon dinner featuring lobster and steak. , ...
(Date:8/4/2015)... Orleans, LA (PRWEB) , ... August 04, 2015 ... ... Catholic institution of higher learning, announced today that its RN to BSN and ... programs have been awarded full accreditation through June 2020 from the Commission ...
(Date:8/4/2015)... ... August 04, 2015 , ... Lightning Labels is pleased to ... that will usher in a new standard of sticker and label-making for the ... meet its twin objectives of quality and quantity without compromising the signature lightning-fast ...
Breaking Medicine News(10 mins):Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3
... internal molecular clock in controlling blood// pressure. , ... strokes occur most frequently in the early-morning hours. Published online ... Sciences, this report points to the novel possibility of modifying ... ,The upswing in heart attacks tracks with rising blood ...
... will be diagnosed with cancer of the colon and rectum ... yearly basis, today’s genetic research news offers some optimism. ... Proceedings of the National Academy of Sciences, led by Zhenghe ... Western Reserve University School of Medicine and Case Comprehensive Cancer ...
... stem cell-based regenerative medicine will help repair diseased tissue. ... epigenetic signals that give stem cells their unique ability ... ,The hype over epigenetic research is because ... manipulating epigenetic marks, cells can be transformed into other ...
... were dug out from the gutter of Ratlam's Christian Hospital ... following recovery of the bones, was granted bail. ... bones of infants, suspected to be of aborted fetuses and ... to 437 from 391 bone pieces found Saturday night. ...
... pointed out that women with a 34 inch waist carry twice ... women who boast of trimmer waists. ,Nearly 5500 women ... by 19% as compared to the figures in 1990. Women fifty ... grave risks encountered by the present lot. ...
... bring down the androgen levels in women. This was reported ... ,Hirsutism is a condition which is characterized by growth ... women. This is mainly due to an increased level of ... ,Spearmint was used in earlier studies to bring down ...
Cached Medicine News:Health News:Reset Your Biological Clock and Prevent Heart Attack! 2Health News:Researchers Identify Cell Pathway in Colon Cancer 2Health News:Epigenetics to Shape Stem Cell Future 2Health News:More Bones of Aborted Fetuses Recovered from Hospital Premises 2Health News:Cancer Risk Pronounced in Women With an Ample Waist 2
... Sprinter balloon incorporates advanced technology, ... crossing ability in the toughest ... will is offered in a ... from the 2.0 4.0 ...
Increased stent scaffolding at the proximal end gives optimal lumen support and 6F guide catheter compatibility and improved tracking offer excellent deliverability. Customized balloon lengths for ea...
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
Medicine Products: